Acid-suppressive Effects of Rabeprazole: Comparing 10mg and 20mg Twice Daily in Japanese Helicobacter Pylori-Negative and -Positive CYP2C19 Extensive Metabolisers

T. Shimatani,M. Moriwaki,J. Xu,S. Tazuma,M. Inoue

DOI: https://doi.org/10.1016/j.dld.2006.06.002

IF: 5.165

2006-01-01

Digestive and Liver Disease

Abstract:Background Rabeprazole 10 mg b.i.d. is often administered as therapy for eradication of Helicobacter pylori (H. pylori) and is also proposed as therapy for refractory gastro-oesophageal reflux disease. However, there has not been a comprehensive assessment of its acid-suppressive effects. Aims To compare the acid-suppressive effects of rabeprazole 10 mg b.i.d. with 20 mg b.i.d. considering H. pylori status. Subjects Thirteen H. pylori-negative and eleven H. pylori-positive Japanese CYP2C19 extensive metabolisers (<35 years). Methods Intragastric pH was measured for 24 h three times in a randomised manner; on day 7 of the repeated administration of rabeprazole 10 mg b.i.d. or 20 mg b.i.d., or a placebo. Results In median intragastric pH value and percent time of pH > 3.0, >4.0, >5.0, >6.0, and >7.0 for 24 h, no significant differences were observed between the two doses in either H. pylori-negative or H. pylori-positive subjects. At either dose, these parameters were significantly higher in H. pylori-positive subjects than in H. pylori-negative subjects. Nocturnal acid breakthrough occurred in seven and two of the thirteen H. pylori-negative subjects and one and two of the eleven H. pylori-positive subjects at each dose, respectively. Conclusions The effects of rabeprazole 10 mg b.i.d. were equal to those of 20 mg b.i.d. in H. pylori-positive subjects; whereas in H. pylori-negative subjects, 20 mg b.i.d. was superior for prevention of nocturnal acid breakthrough.